Immunotherapy before surgery for sarcomatoid mesothelioma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II trial evaluates the safety and effectiveness of administering immunotherapy with nivolumab and ipilimumab prior to surgery in patients with stage I-IIIa sarcomatoid mesothelioma. The study aims to determine the percentage of patients who can undergo surgery after receiving this neoadjuvant treatment and to assess the progression-free survival rate at 12 months. Secondary objectives include evaluating surgical complications and treatment response rates. Patients will undergo imaging studies throughout the trial to monitor disease progression.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Sarcomatoid or sarcomatoid-dominant (\> 50%) biphasic, pleural mesothelioma
* Stage: I-IIIA disease per Union for International Cancer Control (UICC) TNM Classification of Malignant Tumours 8th edition
* Measurable disease or non-measurable disease as defined
* No prior treatment which would be considered treatment for the primary neoplasm or impact the primary endpoint
* No treatment with hormones or other chemotherapeutic agents except for hormones administered for non-disease-related conditions (e.g., insulin for diabetes and or hormonal therapy for breast, prostate cancer etc.)
* Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown

  \* Therefore, for women of childbearing potential only, a negative pregnancy test done =\< 14 days prior to registration is required
* Age \>= 18 years
* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 or Karnofsky \>= 60%
* Absolute neutrophil count (ANC) \>= 1,000/mm\^3
* Leukocytes \>= 2,000/mm\^3
* Platelet count \>= 100,000/mm\^3
* Creatinine =\< 1.5 x upper limit of normal (ULN) OR creatinine clearance \>= 40 mL/min
* Total bilirubin =\<1.5 x ULN, except patients with Gilbert Syndrome who can have total bilirubin \< 3.0 mg/dl
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3.0 x ULN
* Alkaline (alk) phosphatase (phos) =\< 3.0 x ULN
* No active, known or suspected autoimmune disease except for vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger
* No active systemic infection requiring therapy, as well as positive tests for hepatitis B surface antigen or hepatitis C antibody
* No history of any other condition that may require the initiation of anti-tumor necrosis factor alpha (TNFalpha) therapies or other immunosuppressant medications during the study
* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
* STEP 2 ELIGIBILITY CRITERIA: Completion of at least 1 cycle of treatment and not have an unresolved adverse event that would preclude surgery
* STEP 2 ELIGIBILITY CRITERIA: No evidence of progression that would preclude resection
* STEP 2 ELIGIBILITY CRITERIA: ECOG performance status =\< 2 or Karnofsky \>= 60%
* STEP 2 ELIGIBILITY CRITERIA: Predicted forced expiratory volume in 1 second (FEV1) \> 35% and postoperative predicted diffusion capacity of the lung for carbon monoxide (DLCO) \> 35%
* STEP 2 ELIGIBILITY CRITERIA: Registration to step 2 no less than 21 days and no more than 90 days after the last dose of neoadjuvant therapy

Exclusion Criteria:

* No patients deemed to be unresectable or poor surgical candidates
* No patients with chest wall invasion, peritoneal spread, contralateral pleural involvement, mediastinal organ involvement, vertebral involvement, or metastases to contralateral intrathoracic lymph nodes, or any supraclavicular nodes
* No patients with a history of symptomatic interstitial lung disease

Where it's running

• Anchorage Associates in Radiation Medicine
  Anchorage, Alaska, United States Recruiting
• Alaska Breast Care and Surgery LLC
  Anchorage, Alaska, United States Recruiting
• Alaska Oncology and Hematology LLC
  Anchorage, Alaska, United States Recruiting
• Alaska Women's Cancer Care
  Anchorage, Alaska, United States Recruiting
• Katmai Oncology Group
  Anchorage, Alaska, United States Recruiting
• Providence Alaska Medical Center
  Anchorage, Alaska, United States Recruiting

+82 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Aaron Mansfield, MD
• Email: mansfield.aaron@mayo.edu
• Phone: 507-293-0569

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adding a targeted cancer drug to standard therapy for untreated CLL/SLL

  This trial tests whether adding sonrotoclax to zanubrutinib helps people with untreated CLL/SLL live longer without the disease getting worse.

  Recruiting at 259 sites Phase 3 Alliance for Clinical Trials in Oncology · Birmingham, Alabama and 260 other locations · NCT07321652

• Targeted post-surgery radiation plus standard therapy for NSCLC with remaining nodal cancer

  This phase II trial tests whether adding intensity-modulated post-operative radiation therapy to standard chemotherapy or immunotherapy helps people with non-small cell lung cancer and remaining lymph node cancer after surgery.

  Recruiting at 121 sites Phase 2 Alliance for Clinical Trials in Oncology · Jonesboro, Arkansas and 124 other locations · NCT07293247

• Using the PAGODA algorithm to guide FOLFOX dose changes and reduce unplanned chemotherapy delays

  This trial will test whether using the PAGODA algorithm to guide dose changes during FOLFOX chemotherapy for people with gastrointestinal cancers can reduce unplanned treatment delays.

  Recruiting at 391 sites Alliance for Clinical Trials in Oncology · Fairbanks, Alaska and 397 other locations · NCT07283939

• Vor a sid en ib + temozolomide after radiation for IDH-mutant astrocytoma (grade 3)

  This phase 3 trial tests whether adding vorasidenib to the usual temozolomide after radiation helps people with newly diagnosed IDH-mutant astrocytoma (grade 3).

  Recruiting at 176 sites Phase 3 Alliance for Clinical Trials in Oncology · Phoenix, Arizona and 176 other locations · NCT07215910

• Testing Different Dosing Schedules of Lutetium-177Lu PSMA RLT in Advanced Prostate Cancer

  This trial tests if spacing out Lutetium-177Lu PSMA RLT doses adapts to the patient and improves quality of life without shortening life in men with advanced, hormone-resistant prostate cancer.

  Recruiting at 105 sites Phase 3 Alliance for Clinical Trials in Oncology · Anchorage, Alaska and 141 other locations · NCT07200830

• Family genetics: who shares test results with relatives

  This study tests whether letting patients share genetic results with their relatives is as good as doctors sharing the results to help first-degree relatives get genetic testing for hereditary cancer risk.

  Recruiting at 362 sites Alliance for Clinical Trials in Oncology · Birmingham, Alabama and 364 other locations · NCT07143487

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.